Bone density improves in people who switch from tenofovir DF to tenofovir alafenamide
High prevalence of low testosterone among younger and middle-aged ART-treated men in France
People with HIV/HCV co-infection at increased risk of kidney disease and bone disorders
Co-morbidities are common and rising among people with HIV in the US
Tenofovir alafenamide works well and improves kidney and bone markers in older people living with HIV
Less than 100% adherence to HIV therapy, even with viral suppression, can lead to more inflammation and immune activation
Bone loss partially recovers after stopping PrEP, twice-yearly kidney monitoring is enough for most
Switching from tenofovir DF to TAF improves bone and kidney safety
TAF/emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity
